tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Nerve Degeneration D009410 53 associated lipids
Nervous System Diseases D009422 37 associated lipids
Neuritis D009443 4 associated lipids
Neurodermatitis D009450 1 associated lipids
Neuromuscular Diseases D009468 10 associated lipids
Neuromyelitis Optica D009471 2 associated lipids
Neutropenia D009503 15 associated lipids
Nocardia Infections D009617 6 associated lipids
Obesity D009765 29 associated lipids
Oliguria D009846 2 associated lipids
Opportunistic Infections D009894 8 associated lipids
Optic Neuritis D009902 1 associated lipids
Orchitis D009920 1 associated lipids
Osteochondrodysplasias D010009 3 associated lipids
Osteomalacia D010018 5 associated lipids
Osteonecrosis D010020 5 associated lipids
Osteoporosis D010024 12 associated lipids
Ovarian Cysts D010048 4 associated lipids
Pain D010146 64 associated lipids
Pain, Intractable D010148 4 associated lipids
Pancreatic Fistula D010185 2 associated lipids
Pancytopenia D010198 6 associated lipids
Paraproteinemias D010265 2 associated lipids
Paresis D010291 2 associated lipids
Parkinson Disease D010300 53 associated lipids
Paronychia D010304 3 associated lipids
Parotitis D010309 4 associated lipids
Pemphigoid, Benign Mucous Membrane D010390 4 associated lipids
Pemphigoid, Bullous D010391 8 associated lipids
Pemphigus D010392 3 associated lipids
Peptic Ulcer D010437 19 associated lipids
Peptic Ulcer Perforation D010439 3 associated lipids
Perceptual Disorders D010468 3 associated lipids
Pericarditis D010493 6 associated lipids
Periodontal Pocket D010514 9 associated lipids
Peripheral Nervous System Diseases D010523 33 associated lipids
Peritoneal Neoplasms D010534 16 associated lipids
Pharyngitis D010612 2 associated lipids
Pityriasis D010915 3 associated lipids
Polyneuropathies D011115 3 associated lipids
Postoperative Complications D011183 5 associated lipids
Poxviridae Infections D011213 1 associated lipids
Precancerous Conditions D011230 48 associated lipids
Pregnancy Complications D011248 19 associated lipids
Priapism D011317 1 associated lipids
Proteinuria D011507 30 associated lipids
Prurigo D011536 4 associated lipids
Pruritus Ani D011538 2 associated lipids
Pruritus Vulvae D011539 1 associated lipids
Pseudohypoaldosteronism D011546 1 associated lipids
Pseudomonas Infections D011552 25 associated lipids
Psoriasis D011565 47 associated lipids
Psychoses, Substance-Induced D011605 7 associated lipids
Pterygium D011625 3 associated lipids
Pulmonary Veno-Occlusive Disease D011668 1 associated lipids
Purpura, Thrombotic Thrombocytopenic D011697 6 associated lipids
Rectal Diseases D012002 1 associated lipids
Rectal Fistula D012003 2 associated lipids
Red-Cell Aplasia, Pure D012010 4 associated lipids
Reflex Sympathetic Dystrophy D012019 4 associated lipids
Respiration Disorders D012120 5 associated lipids
Respiratory Insufficiency D012131 10 associated lipids
Respiratory Tract Neoplasms D012142 2 associated lipids
Retinoblastoma D012175 12 associated lipids
Rhabdomyolysis D012206 9 associated lipids
Rheumatoid Nodule D012218 1 associated lipids
Rosacea D012393 13 associated lipids
Rotavirus Infections D012400 1 associated lipids
Rupture D012421 2 associated lipids
Sarcoidosis D012507 13 associated lipids
Sarcoma, Kaposi D012514 6 associated lipids
Osteosarcoma D012516 50 associated lipids
Scalp Dermatoses D012536 11 associated lipids
Sclerosis D012598 5 associated lipids
Dermatitis, Seborrheic D012628 10 associated lipids
Seizures D012640 87 associated lipids
Shock D012769 11 associated lipids
Shock, Septic D012772 11 associated lipids
Sinusitis D012852 9 associated lipids
Skin Diseases, Vesiculobullous D012872 5 associated lipids
Skin Neoplasms D012878 12 associated lipids
Sleep Wake Disorders D012893 7 associated lipids
Spinal Cord Injuries D013119 34 associated lipids
Stomach Ulcer D013276 75 associated lipids
Stomatitis D013280 14 associated lipids
Subarachnoid Hemorrhage D013345 17 associated lipids
Surgical Wound Infection D013530 7 associated lipids
Tachycardia D013610 7 associated lipids
Telangiectasis D013684 2 associated lipids
Testicular Diseases D013733 15 associated lipids
Thinness D013851 11 associated lipids
Thrombocytopenia D013921 15 associated lipids
Thrombophlebitis D013924 6 associated lipids
Thrombosis D013927 49 associated lipids
Thymus Neoplasms D013953 15 associated lipids
Thyroid Diseases D013959 8 associated lipids
Thyroiditis, Autoimmune D013967 9 associated lipids
Tinea D014005 5 associated lipids
Tinea Capitis D014006 1 associated lipids
Tongue Diseases D014060 2 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Busuttil RW and Lake JR Role of tacrolimus in the evolution of liver transplantation. 2004 Transplantation pmid:15201686
Gjertson DW et al. The relative effects of FK506 and cyclosporine on short- and long-term kidney graft survival. 1995 Transplantation pmid:8545861
Vincenti F A decade of progress in kidney transplantation. 2004 Transplantation pmid:15201687
Andrades KM et al. Modulation of Candida albicans virulence by antirejection immunosuppressant drugs. 2013 Transplantation pmid:23380869
Shirakata Y et al. Inhibitory effect of plasma FKBP12 on immunosuppressive activity of FK506. 1995 Transplantation pmid:8545894
Bunnapradist S et al. Graft survival following living-donor renal transplantation: a comparison of tacrolimus and cyclosporine microemulsion with mycophenolate mofetil and steroids. 2003 Transplantation pmid:12865780
Rodrigo E et al. Within-Patient Variability in Tacrolimus Blood Levels Predicts Kidney Graft Loss and Donor-Specific Antibody Development. 2016 Transplantation pmid:26703349
Hashimoto T et al. Treatment with FK506 prevents rejection of rat colon allografts. 1994 Transplantation pmid:7516586
Gonwa T et al. Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years. 2003 Transplantation pmid:12829910
Briggs D et al. Effects of immediate switch from cyclosporine microemulsion to tacrolimus at first acute rejection in renal allograft recipients. 2003 Transplantation pmid:12829912
Utsugi R et al. Induction of transplantation tolerance with a short course of tacrolimus (FK506): I. Rapid and stable tolerance to two-haplotype fully mhc-mismatched kidney allografts in miniature swine. 2001 Transplantation pmid:11391221
Krentz AJ Posttransplantation Diabetes Mellitus in FK-506-Treated Renal Transplant Recipients: Analysis of Incidence and Risk Factors. Transplantation 2001; 72: 1655. 2001 Transplantation pmid:11726815
Andrés A et al. A randomized trial comparing renal function in older kidney transplant patients following delayed versus immediate tacrolimus administration. 2009 Transplantation pmid:19898206
Larsen JL et al. Tacrolimus and sirolimus cause insulin resistance in normal sprague dawley rats. 2006 Transplantation pmid:16926589
Welberry Smith MP et al. Alemtuzumab induction in renal transplantation permits safe steroid avoidance with tacrolimus monotherapy: a randomized controlled trial. 2013 Transplantation pmid:24056618
Fisher NC et al. Chronic renal failure following liver transplantation: a retrospective analysis. 1998 Transplantation pmid:9679823
Ericzon BG et al. The effect of FK506 treatment on pancreaticoduodenal allotransplantation in the primate. 1992 Transplantation pmid:1376501
de Graav GN et al. A Randomized Controlled Clinical Trial Comparing Belatacept With Tacrolimus After De Novo Kidney Transplantation. 2017 Transplantation pmid:28403127
Solez K et al. Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tarolimus versus cyclosporine: a report of the FK506 Kidney Transplant Study Group. 1998 Transplantation pmid:9884269
Bronster DJ et al. Tacrolimus-associated mutism after orthotopic liver transplantation. 2000 Transplantation pmid:11014653
Newell KA et al. Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression. 1996 Transplantation pmid:8779685
Tan HP et al. Living-related donor renal transplantation in HIV+ recipients using alemtuzumab preconditioning and steroid-free tacrolimus monotherapy: a single center preliminary experience. 2004 Transplantation pmid:15591960
Squifflet JP et al. Dose optimization of mycophenolate mofetil when administered with a low dose of tacrolimus in cadaveric renal transplant recipients. 2001 Transplantation pmid:11468536
Theruvath TP et al. Control of antidonor antibody production with tacrolimus and mycophenolate mofetil in renal allograft recipients with chronic rejection. 2001 Transplantation pmid:11468538
Zervos XA et al. Comparison of tacrolimus with microemulsion cyclosporine as primary immunosuppression in hepatitis C patients after liver transplantation. 1998 Transplantation pmid:9583863
Moreau C et al. Interaction between tacrolimus and omeprazole in a pediatric liver transplant recipient. 2006 Transplantation pmid:16477241
Bronster DJ et al. Demyelinating sensorimotor polyneuropathy after administration of FK506. 1995 Transplantation pmid:7535959
Guerville F et al. Transplantation with pathologic kidneys to improve the pool of donors: an example of shunt nephritis. 2012 Transplantation pmid:22487813
Swinnen LJ et al. Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder. 2008 Transplantation pmid:18645482
Welberry Smith MP and Baker RJ The author's reply. 2014 Transplantation pmid:24978039
Chakrabarti P et al. Outcome after steroid withdrawal in pediatric renal transplant patients receiving tacrolimus-based immunosuppression. 2000 Transplantation pmid:11003353
Hougardy JM et al. Conversion from Prograf to Advagraf among kidney transplant recipients results in sustained decrease in tacrolimus exposure. 2011 Transplantation pmid:21192316
Neuhaus P et al. Quadruple tacrolimus-based induction therapy including azathioprine and ALG does not significantly improve outcome after liver transplantation when compared with standard induction with tacrolimus and steroids: results of a prospective, randomized trial. 2000 Transplantation pmid:10868638
Mohamed MA et al. TGF-beta expression in renal transplant biopsies: a comparative study between cyclosporin-A and tacrolimus. 2000 Transplantation pmid:10755567
Anil Kumar MS et al. Comparison of steroid avoidance in tacrolimus/mycophenolate mofetil and tacrolimus/sirolimus combination in kidney transplantation monitored by surveillance biopsy. 2005 Transplantation pmid:16210969
van Boekel GA et al. Effect of mild diarrhea on tacrolimus exposure. 2012 Transplantation pmid:22955188
Guthery SL et al. Determination of risk factors for Epstein-Barr virus-associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment. 2003 Transplantation pmid:12698085
Ellis D et al. Renal transplantation in children managed with lymphocyte depleting agents and low-dose maintenance tacrolimus monotherapy. 2007 Transplantation pmid:17589338
Webb NJ et al. Corticosteroid-free Kidney Transplantation Improves Growth: 2-Year Follow-up of the TWIST Randomized Controlled Trial. 2015 Transplantation pmid:25539467
Yoo MC et al. Steroid-free Liver Transplantation Using Rabbit Antithymocyte Globulin Induction in 500 Consecutive Patients. 2015 Transplantation pmid:25539464
Shapiro R et al. Tacrolimus in pediatric renal transplantation. 1996 Transplantation pmid:8990356
Przepiorka D et al. Allogeneic transplantation for advanced leukemia: improved short-term outcome with blood stem cell grafts and tacrolimus. 1996 Transplantation pmid:8990368
Ko S et al. The pharmacokinetic benefits of newly developed liposome-incorporated FK506. 1994 Transplantation pmid:7526494
Holländer GA et al. Disruption of T cell development and repertoire selection by calcineurin inhibition in vivo. 1994 Transplantation pmid:7526495
Gruessner RW et al. A multicenter analysis of the first experience with FK506 for induction and rescue therapy after pancreas transplantation. 1996 Transplantation pmid:8600635
Cezário ES et al. Gingival overgrowth in renal transplant subjects medicated with tacrolimus in the absence of calcium channel blockers. 2008 Transplantation pmid:18212628
Rayar M et al. High Intrapatient Variability of Tacrolimus Exposure in the Early Period After Liver Transplantation Is Associated With Poorer Outcomes. 2018 Transplantation pmid:29315140
Gillard P et al. Comparison of sirolimus alone with sirolimus plus tacrolimus in type 1 diabetic recipients of cultured islet cell grafts. 2008 Transplantation pmid:18212631
Kuypers DR et al. Clinically relevant drug interaction between voriconazole and tacrolimus in a primary renal allograft recipient. 2006 Transplantation pmid:16794545
Chan L et al. Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients. 2010 Transplantation pmid:20517177